In Brief: Cyberonics
This article was originally published in The Gray Sheet
Executive SummaryCyberonics: President and CEO Allen Hill resigns due to "personal reasons and family commitments." Hill will continue as a consultant for Cyberonics at the request of the company's board. Chairman and Executive VP Reese Terry will assume Hill's duties on an interim basis while a replacement is sought. The Webster, Texas-based firm also has tapped William Duffell for the position of VP, clinical and regulatory affairs; he replaces Joachim Wernicke, who vacated the post in December. Previously, Duffel was director, regulatory affairs and quality assurance for Bristol-Myers Squibb...
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.